2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4963 AML1-ETO orchestrates PD1H repression to enforce leukemic stemness and drive differentiation arrest via epigenetic remodeling in t(8;21) AML

Yu Liu, Wenbing Liu2, Shaowei Qiu, MD3, Ying Wang, MD, PhD4, Min Wang, PhD5, Jianxiang Wang Sr, MD, PhD6, Runxia Gu, MD7
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China

Objectives: PD1H is a critical immune checkpoint in acute myeloid leukemia (AML). Previous studies have largely focused on its immunomodulatory roles within the tumor microenvironment, whereas its cell-intrinsic functions and regulatory architecture in leukemic cells remain poorly understood. Notably, our preliminary data uncovered pronounced subtype-specific heterogeneity, with t(8;21) AML exhibiting the lowest PD1H levels and remarkable intra-patient variability, suggesting a distinct regulatory framework in this subtype. In this study, we therefore sought to systematically elucidate the expression landscape, functional significance, and regulatory mechanism of PD1H in t(8;21) AML.

Methods: Transcriptomic data from multiple public AML cohorts (n=1024) were integrated to characterize PD1H expression heterogeneity across subtypes. The functional and prognostic relevance of PD1H was further evaluated using expression profiles of t(8;21) AML patients from our center (n=42) and validated using the HOVON cohort (n=46). Single-cell RNA sequencing (n=5) on t(8;21) AML samples was performed to delineate PD1H distribution across distinct leukemic subsets. Lentivirus-mediated overexpression of PD1H, followed by flow cytometry assays, was employed to evaluate its functional impact on cellular stemness and differentiation. Integrative multi-omics analyses, including ATAC-seq, RNA-seq, and ChIP-seq, were performed and analyzed comprehensively to characterize the regulatory profile, and further validated using the AML1-ETO-bearing cell models.

Results:

We initially observed that PD1H expression varied significantly across AML subtypes, with t(8;21) AML displaying the lowest levels and considerable intra-patient heterogeneity. Notably, t(8;21) AML patients with lower PD1H expression experienced significantly shorter event-free survival (EFS, p=0.006) and a higher frequency of KIT-D816 mutations (35% vs. 10%), suggesting a high-risk subset with unfavorable outcomes.

To further delineate the functional landscape associated with PD1H in t(8;21) AML, we classified the t(8;21) AML patients (n=42) administered in our center based on PD1H expression levels. The PD1H-low group was strongly enriched for leukemic stem cell (LSC) signatures, while the PD1H-high group was significantly enriched for granulocytic and monocytic signatures and exhibited a more differentiated gene expression profile, suggesting a block at later stages of myeloid maturation. These findings were further validated in the HOVON cohort (n=46).

To delve deeper into its expression patterns in t(8;21) AML, we performed single-cell RNA sequencing on 5 t(8;21) AML samples, and our analysis demonstrated that PD1H was preferentially expressed in monocyte-like leukemic cells, whereas it was barely detectable in other subpopulations. These findings further suggested the differentiation stage-dependent expression pattern of PD1H in t(8;21) AML.

Functionally, forced expression of PD1H in AML1-ETO-expressing leukemic cells significantly reduced surface levels of the stemness marker CD117 and concurrently upregulated myeloid differentiation antigens, reinforcing an inverse correlation between PD1H expression and differentiation hierarchy.

Mechanistically, genetic ablation of AML1-ETO led to robust PD1H upregulation, while inducible AML1-ETO expression in U937 cells suppressed PD1H in a dose-dependent manner. Integrated ChIP-seq and ATAC-seq demonstrated that AML1-ETO directly binds to the PD1H promoter, reducing chromatin accessibility and repressing transcription. This repression was accompanied by enhanced differentiation blockade, indicating that AML1-ETO-mediated PD1H silencing is a critical event sustaining leukemic stemness and driving differentiation arrest.

Conclusions: Our study characterizes PD1H heterogeneity in t(8;21) AML and establishes PD1H as a critical downstream effector in AML1-ETO-driven leukemogenesis. We demonstrate that the AML1-ETO fusion protein directly binds to the PD1H promoter and epigenetically silences its transcription, thereby enforcing leukemic stemness and blocking myeloid maturation, a process that contributes to adverse prognosis in this subtype. Beyond its mechanistic implications, these findings position PD1H as a promising prognostic biomarker and an attractive therapeutic target, with the potential to improve risk stratification and guide targeted therapeutic strategies in t(8;21) AML.

Yu Liu: No relevant conflicts of interest to declare.